Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Add some on this dip
NO ONE can tell you that shares are worthless except a bankruptcy court judge. Any paperwork written otherwise means squat. And we’re a long way off from a judge’s conclusion.
Nice. Good for you.
Is RH trading this today? Ya know there’s a lot of penny chasers on that app.
Starting to simmer
Nice $1.29 AH. This has to start hitting scanners.
I’m back in. Added on the news.
Agreed. Added some today.
I have no idea. Only thing recent is that they didn’t lose as much money as expected on their quarterly. Which is what the merger and shake up was planned to do, tighten the reigns and set new management, etc. Plan is in motion I guess.
CNN Business Price target $3.80.
Recognia Reasearch Firm rates strong buy short and mid term.
Marketwatch.com has buy rating.
https://money.cnn.com/quote/forecast/forecast.html?symb=SLRX
Time to average down. I just didn’t want to sink any more money here but it only makes sense.
A giant turd. I’ve been holding since merger with FLKS and than it RS. My cost basis is friggin $17.44.
Pluristem updates 28-day follow up for ventilator-dependent COVID-19 patients https://seekingalpha.com/news/3574445
April revenues are greater than the entire first quarters revenues! That’s pretty good news.
https://www.businesswire.com/news/home/20200514005289/en/NovaBay-Pharmaceuticals-Issues-Letter-Stockholders
Getting some attention today.
https://m.benzinga.com/article/16008896
Worth a shot today. I’m in.
Why the sudden jump up here?
Very strong premarket. This could get crazy today.
This post needs to be tacked up top.
NovaBay Pharmaceuticals Appoints Andrew D. Jones Chief Financial Officer
May 05, 2020 6:50 AM ETBusiness WireNovaBay Pharmaceuticals, Inc. (NBY)
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the appointment of Andrew D. Jones as Chief Financial Officer and Treasurer, effective May 1, 2020. Mr. Jones brings to NovaBay more than 20 years of finance and accounting experience primarily in the life sciences industry. He replaces Lynn Christopher, who assumed these positions on an interim basis in April 2020 and will consult to NovaBay to support a smooth transition.
“We are delighted to secure a well-qualified professional to fill our executive finance position on a permanent basis and to do so very quickly,” said Justin Hall, NovaBay CEO. “Andrew has served every critical function in finance and accounting from high-level strategic planning and financial modeling, budgeting and cash management, to technical accounting, audit and tax compliance, and managing daily accounting operations. The breadth of his finance and accounting experience, his background in the life sciences industry and relevant public company accounting expertise make him an excellent fit.”
“Serving as NovaBay’s CFO will allow me to use my entire skillset in an executive capacity in a dynamic environment,” said Mr. Jones. “I’m committed to working closely with the NovaBay team to ensure financial accountability and prudence, and to achieve our goals for growth and business success.”
Mr. Jones most recently served as an independent consultant, helping companies to meet their accounting and finance requirements. He previously served as Vice President, Finance of MyoScience, Inc., a commercial-stage medical device company, through its acquisition by Pacira BioSciences in August 2019. In this position, he was responsible for senior management and Board-level reporting, and overseeing all accounting and finance functions, including strategic planning and business development decisions that resulted in revenue growth and gross margin improvements. Before that, Mr. Jones was Senior Director of Finance and Controller of Armetheon, Inc., a late-stage drug development company, and Corporate Controller of Asante Solutions, Inc., a medical device company acquired by Bigfoot Biomedical, Inc., and Genelabs Technologies, Inc. (GNLB), a Nasdaq-listed company subsequently acquired by GlaxoSmithKline. Earlier in his career he was Transaction Services, Senior Manager at PricewaterhouseCoopers providing clients with M&A advisory services, and a Senior Associate at Price Waterhouse, LLP. Mr. Jones received a BA in business administration from the University of Washington.
On the move now!
Same
Any buys at 015 and below is a gift. Easy money.
Good stuff. FOMO. No profit taking here.
AKRX filing chapter 11 by May 1st
Enphase, Paylocity gain amid S&P index moves https://seekingalpha.com/news/3565012-enphase-paylocity-gain-amid-s-and-p-index-moves
A text message a just received from a friend in Morocco:
Breaking News.
Israel has found a possible 100% cure for Coronavirus.
--------------------------------------------------
The Israeli coronavirus drug reportedly with a 100% success rate even among severely ill patients is being tested in the United States for the first time.
Pluristem Therapeutics Inc., a biotech company based in Haifa/Israel, reported that seven patients who were at a high risk of death due to respiratory failure, multi-system organ failure, including heart and kidney failure survived after receiving this medication.
The seven patients were treated with Pluristem’s allogeneic placental expanded (PLX) cells. Essentially, these cells can potentially suppress or reverse the dangerous over-activation of the immune system that causes death in many coronavirus patients.
Now, a critical COVID-19 patient in the US has been treated with PLX cell therapy at Holy Name Medical Center in New Jersey. The results of the treatment have yet to be released.
Pluristem Therapeutics uses placentas to grow smart cells and programs them to secrete therapeutic proteins in the bodies of sick people.
company CEO and president Yaky Yanay said Thursday that a trial will come soon and, once conducted, he hopes that “approval can be very fast.” Upon receiving the green light from regulators, he said, massive quantities of treatment can be prepared. “We can manufacture cells to treat thousands very quickly,” he said.
Treatment consists of 15-milliliter doses of cells — known as PLacental eXpanded cells — administered in simple inter-muscular injections. Once in the body, Yanay said that the cells become like “a small factory that generates therapeutic proteins.”
He explained: “Most drugs we know are administered in the quantity we need, but this is a ‘drug’ that can sense the human body’s environment, and based on the signals that the cells receive from the body, they secrete therapeutic proteins that push the body toward regeneration.”
The cells secrete two types of proteins. One reduces inflammation; the other is to regulate the immune system. Yanay hopes these so-called immunomodulation proteins can slam the brakes on the immune system to stop it turning on itself, as commonly happens with critical coronavirus patients.
“They stop the body from attacking its own organs by having the placenta cells secrete immunomodulatory factors, basically relaxing the immune system, as the other proteins reduce inflammation,” said Yanay.
He elaborated: “Patients who are in severe condition and dying are actually dying from a severe respiratory condition. What is actually happening is there is a very high level of inflammation and at a certain point the immune system of the patient will attack [the patient], mostly in the lungs.”
Until now, Pluristem’s technology has been largely used to treat people suffering from poor blood flow to the legs, but the company’s scientists were able to quickly repurpose the cells to treat coronavirus patients.
“We take cells from the placenta after full-term delivery and we have developed technology to expand the cells to very large numbers, in an environment that mimics the human body,” Yanay said. “The technology allows us to treat more than 20,000 people from a single placenta.”
His team “programs” the cells, which then have a wide range of proteins they can secrete. The cells don’t just deliver the proteins but also “adjust the level of secretion based on signals they receive from the body,” he said.
Yanay stated that Pluristem, which is based in Haifa, will carry on treating people using patient-by-patient approvals while working as quickly as possible for full approval by regulators.
“We are receiving many inquiries and requests for treatment from health care providers and families worldwide,” he said. “In parallel with our planned clinical trial, we expect to continue treating patients under compassionate use through the appropriate regulatory clearances in the United States and Israel, as well as expanding treatment under compassionate use in other countries.
“Our main focus remains, however, the initiation of a multinational clinical study,” he said, adding that he was hopeful “cell therapy is a very good candidate to tackle a complex disease that is attacking several organs.”
Thank you to Zack Gold (on Facebook) who alerted yesterday at .0055. Quadruple money in one day and one hour!
Geeez. I thought it would take all day to hit 2 cents!
So than how fast and at what quantities can they get the product from China?
Does anyone know how fast and at what quantities NBY can produce test kits once FDA approves?
IBIO was stuck just under .40 for months, right before it blew up to $4!
NovaBay Pharmaceuticals Inks Deal to Become Exclusive US Distributor of COVID-19 Antibody Rapid Point-of-Care Test
4/20/20, 7:36 AM
07:36 AM EDT, 04/20/2020 (MT Newswires) -- NovaBay Pharmaceuticals (NBY) said pre-market Monday that it has signed a deal with Shenzhen Microprofit Biotech Co., Ltd. to become the exclusive US distributor of the fluorecare SARS-CoV-2 IgG & IgM antibody point of care test kit to be administered by health care professionals.
The finger prick test determines the presence of COVID-19 or a potential indication of antibody immunity to the respiratory disease for which currently there is no treatment, according to NovaBay.
The pharmaceutical firm said that it will submit the fluorecare test kit to the US Food and Drug Administration under Emergency Authorization Use. It will also seek a permanent FDA 510(k) clearance for the test kit for continued use once the federal government declares an end to the state of emergency.
Price: 1.5400, Change: +0.78, Percent Change: +102.63
http://www.mtnewswires.com Copyright © 2020 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
NovaBay Pharmaceuticals Inks Deal to Become Exclusive US Distributor of COVID-19 Antibody Rapid Point-of-Care Test
4/20/20, 7:36 AM
07:36 AM EDT, 04/20/2020 (MT Newswires) -- NovaBay Pharmaceuticals (NBY) said pre-market Monday that it has signed a deal with Shenzhen Microprofit Biotech Co., Ltd. to become the exclusive US distributor of the fluorecare SARS-CoV-2 IgG & IgM antibody point of care test kit to be administered by health care professionals.
The finger prick test determines the presence of COVID-19 or a potential indication of antibody immunity to the respiratory disease for which currently there is no treatment, according to NovaBay.
The pharmaceutical firm said that it will submit the fluorecare test kit to the US Food and Drug Administration under Emergency Authorization Use. It will also seek a permanent FDA 510(k) clearance for the test kit for continued use once the federal government declares an end to the state of emergency.
Price: 1.5400, Change: +0.78, Percent Change: +102.63
http://www.mtnewswires.com Copyright © 2020 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
NovaBay Pharmaceuticals Inks Deal to Become Exclusive US Distributor of COVID-19 Antibody Rapid Point-of-Care Test
4/20/20, 7:36 AM
07:36 AM EDT, 04/20/2020 (MT Newswires) -- NovaBay Pharmaceuticals (NBY) said pre-market Monday that it has signed a deal with Shenzhen Microprofit Biotech Co., Ltd. to become the exclusive US distributor of the fluorecare SARS-CoV-2 IgG & IgM antibody point of care test kit to be administered by health care professionals.
The finger prick test determines the presence of COVID-19 or a potential indication of antibody immunity to the respiratory disease for which currently there is no treatment, according to NovaBay.
The pharmaceutical firm said that it will submit the fluorecare test kit to the US Food and Drug Administration under Emergency Authorization Use. It will also seek a permanent FDA 510(k) clearance for the test kit for continued use once the federal government declares an end to the state of emergency.
Price: 1.5400, Change: +0.78, Percent Change: +102.63
http://www.mtnewswires.com Copyright © 2020 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
NovaBay Pharmaceuticals Inks Deal to Become Exclusive US Distributor of COVID-19 Antibody Rapid Point-of-Care Test
4/20/20, 7:36 AM
07:36 AM EDT, 04/20/2020 (MT Newswires) -- NovaBay Pharmaceuticals (NBY) said pre-market Monday that it has signed a deal with Shenzhen Microprofit Biotech Co., Ltd. to become the exclusive US distributor of the fluorecare SARS-CoV-2 IgG & IgM antibody point of care test kit to be administered by health care professionals.
The finger prick test determines the presence of COVID-19 or a potential indication of antibody immunity to the respiratory disease for which currently there is no treatment, according to NovaBay.
The pharmaceutical firm said that it will submit the fluorecare test kit to the US Food and Drug Administration under Emergency Authorization Use. It will also seek a permanent FDA 510(k) clearance for the test kit for continued use once the federal government declares an end to the state of emergency.
Price: 1.5400, Change: +0.78, Percent Change: +102.63
http://www.mtnewswires.com Copyright © 2020 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
I sold my last couple million shares yesterday as a market order and got $2.24. Haha. It’s really not even funny. I’m one of the lucky ones who never paid more than 0003 for shares. Not sure why a market order is executed when there’s no bid.
You know the market is closed on Good Friday, right?